XOMA Royalty (NASDAQ:XOMA) CEO Buys $2,505,000.00 in Stock

XOMA Royalty Corporation (NASDAQ:XOMA) CEO Owen Hughes purchased 100,000 shares of the company’s stock in a transaction dated Thursday, December 4th. The stock was purchased at an average price of $25.05 per share, with a total value of $2,505,000.00. Following the transaction, the chief executive officer owned 102,000 shares of the company’s stock, valued at approximately $2,555,100. This represents a 5,000.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

XOMA Royalty Price Performance

NASDAQ XOMA traded up $0.58 during trading hours on Monday, reaching $30.49. The company’s stock had a trading volume of 63,193 shares, compared to its average volume of 47,163. The company has a debt-to-equity ratio of 1.07, a quick ratio of 3.91 and a current ratio of 3.91. The company’s 50-day moving average is $34.22 and its two-hundred day moving average is $30.89. XOMA Royalty Corporation has a fifty-two week low of $18.35 and a fifty-two week high of $39.92. The stock has a market cap of $377.56 million, a PE ratio of 41.20 and a beta of 0.94.

XOMA Royalty (NASDAQ:XOMA) last announced its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.33). XOMA Royalty had a net margin of 32.28% and a return on equity of 2.91%. The business had revenue of $9.35 million during the quarter, compared to analysts’ expectations of $11.47 million. Analysts forecast that XOMA Royalty Corporation will post -1.41 EPS for the current year.

Institutional Trading of XOMA Royalty

Institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. raised its position in shares of XOMA Royalty by 3,436.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after buying an additional 756 shares during the period. Tower Research Capital LLC TRC increased its stake in XOMA Royalty by 203.1% during the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,523 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of XOMA Royalty by 266.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 2,346 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of XOMA Royalty by 13.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 543 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of XOMA Royalty in the 2nd quarter valued at about $116,000. 95.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

XOMA has been the topic of several recent research reports. Wall Street Zen downgraded XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Zacks Research lowered shares of XOMA Royalty from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 18th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of XOMA Royalty in a report on Tuesday, November 25th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $69.50.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.